TearClear Email Format
Pharmaceutical ManufacturingMassachusetts, United States2-10 Employees
TearClear is a small ophthalmic pharmaceutical company based in Boston, Massachusetts. It aims to change how topical medications are delivered to the ocular surface through a novel delivery platform that routes drugs to the eye while removing preservatives before they reach the surface, with the goal of improving safety and patient adherence. Its lead product candidates address glaucoma, with the potential to expand into additional ocular indications using the same delivery approach. The company operates in the ophthalmic pharmaceutical manufacturing sector, serving clinicians and patients who rely on eye-drop therapies. As a small team, TearClear is advancing its lead program and a broader development pipeline. In September 2022, it announced the launch of TC-002, latanoprost ophthalmic solution 0.005%, as its lead product candidate.